The prognostic importance of neuronatin positivity as immunohistochemical in patients with lung adenocarcinoma in the development of brain metastasis.

To search the prognostic significance of the neuronatin (NNAT) protein diagnosed with lung adenocarcinoma in the occurence of brain metastasis. Sixty-six of 200 patients diagnosed with lung adenocarcinoma who received radiotherapy (RT) between 2014 and 2017 were included in the study. A total of 66 patients, 33 (50%) with brain pathology and 33 (50%) with lung pathology, were analyzed retrospectively. Furthermore NNAT-immune-reactivity score (IRS) and nuclear positivity were analyzed in terms of pathological factors. In 33 cases where primary tumor pathology was studied, a statistically borderline significant effect was found for the N stage and a statistically significant effect on overall survival (OS) for nuclear positivity. While OS was 7.6 months in nucleus positively stained (PNS) cases, it was 24.4 months in negatively stained (NNS) cases. While the survival of NNAT-IRS positive cases without cranial metastasis was 20.7 months, the survival of the negative group without cranial metastasis was 61.2 months. The survival of cases with PNS without cranial metastasis was 7.1 months, while the survival of cases with NNS results without cranial metastasis was 52.1 months. In cases where intracranial pathologies, the number of intracranial metastases and the presence of extracranial metastases were found to be statistically significant independent factors (p < 0.001, p < 0.001). With NNAT study in initial pathological tissues of patients diagnosed with lung adenocarcinoma, especially nuclear positivity and NNAT-IRS positivity, a strong prediction can be made about the occurrence of brain metastasis.